Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
D000903:Antibiotics, Antineoplastic / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D047630:Depsipeptides / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics*; D056572:Histone Deacetylase Inhibitors / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000503:physiopathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000503:physiopathology
D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin